文献速递泌尿男性生殖肿瘤头颈与中枢神经肿瘤

纳武利尤单抗治疗肾细胞癌脑转移的疗效与安全性:GETUG-AFU 26 NIVOREN II期研究

Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
PubMed 文献 · J Clin Oncol · 2019-06-13

该II期研究评估纳武利尤单抗在含透明细胞肾细胞癌(ccRCC)脑转移患者中的活性与安全性,前瞻性纳入73例无症状脑转移患者,分为未治疗组(A组39例)和经治组(B组34例)。A组颅内缓解率仅12%,多发病灶或直径大于1 cm者无客观缓解;中位颅内无进展生存期A组2.7个月、B组4.8个月。纳武利尤单抗耐受良好,但未经治疗脑转移患者活性有限,建议免疫检查点抑制剂前考虑脑影像和局部治疗。

要点

  • 未经治疗脑转移患者颅内缓解率仅12%,多发病灶或直径大于1 cm者无客观缓解。
  • 中位颅内无进展生存期A组2.7个月,B组4.8个月,校正风险比2.04。
  • A组72%患者需后续脑局部治疗,纳武利尤单抗耐受良好无意外毒性。

核心结论

  • 纳武利尤单抗在未经治疗的ccRCC脑转移患者中活性有限。
  • 建议转移性ccRCC患者在接受免疫检查点抑制剂前考虑脑影像检查和局部治疗。

研究设计与样本

  • GETUG-AFU 26 NIVOREN为多中心II期试验,评估纳武利尤单抗在血管内皮生长因子靶向治疗失败的转移性ccRCC患者中的活性与安全性。
  • 前瞻性识别无症状脑转移患者并专门行脑评估,分为A组(未治疗脑转移,39例)和B组(经治脑转移,34例),主要终点为A组颅内缓解率。

主要发现

  • A组颅内缓解率为12%,多发病灶或直径大于1 cm的脑病灶患者无客观缓解。
  • A组中位颅内无进展生存期2.7个月(95% CI,2.3至4.6个月),B组4.8个月(95% CI,3.0至8.0个月),校正风险比2.04(95% CI,1.08至3.83)。
  • A组12个月总生存率67%(95% CI,49.6%至79.1%),B组59%(95% CI,40.6%至73.2%)。
  • A组72%患者需后续脑局部治疗,纳武利尤单抗耐受良好,无意外毒性。

临床怎么用

  • 对ccRCC脑转移患者,免疫检查点抑制剂治疗前应行脑影像评估并考虑局部治疗。
  • 纳武利尤单抗单药对未经治疗脑转移的颅内活性有限,需密切监测并计划后续局部治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Nivolumab is standard of care for patients with metastatic clear cell renal cell carcinoma (ccRCC) after failure of antiangiogenic therapies, but its activity on brain metastases from ccRCC remains unknown, because these patients were excluded from pivotal studies. We aimed to assess the activity of nivolumab in this population. METHODS: The GETUG-AFU 26 NIVOREN phase II trial assessed the activity and safety of nivolumab in patients with metastatic ccRCC who failed vascular endothelial growth factor-directed therapies (ClinicalTrials.gov identifier: NCT03013335). Patients with asymptomatic brain metastases were prospectively identified and underwent dedicated brain evaluation. Two cohorts were constituted: cohort A comprised patients with previously untreated brain metastases, and cohort B comprised patients whose brain metastases underwent prior therapy. The primary end point was intracranial response rate in cohort A. RESULTS: Seventy-three patients with brain metastases were included: 39 in cohort A and 34 in cohort B. Intracranial response rate was 12% in cohort A; no objective response was reported in patients with brain lesions that were multiple or larger than 1 cm. Median intracranial progression-free survival was 2.7 months (95% CI, 2.3 to 4.6 months) in cohort A and 4.8 months (95% CI, 3.0 to 8.0 months) in cohort B, with adjusted hazard ratio of 2.04 (95% CI, 1.08 to 3.83). Overall survival rate at 12 months was 67% (95% CI, 49.6% to 79.1%) in cohort A and 59% (95% CI, 40.6% to 73.2%) in cohort B. Most patients in cohort A (72%) needed subsequent focal brain therapy. Nivolumab was well tolerated, with no unexpected toxicity. CONCLUSION: Nivolumab activity is limited in patients with untreated brain metastases from ccRCC. Brain imaging and focal therapy should be considered before immune checkpoint inhibitors in patients with metastatic ccRCC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Flippot R, Dalban C, Laguerre B, et al. Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. J Clin Oncol. 2019. PMID: 31194611. doi:10.1200/JCO.18.02218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。